|
WINNIPEG, Manitoba – February 9, 2010 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, today announces a non-brokered private placement offering (the “Offering”) of up to 7,150,000 units (“Units”) at a price of $0.07 per Unit for gross proceeds of up to $500,500. Each Unit will be comprised of one common share of the Company (a “Share”) and one Share purchase warrant (a “Warrant”).
Read More
|
|
WINNIPEG, Manitoba – January 8, 2010 – Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, announces that in connection with its recently announced partnership with Inverness Medical Innovations (“Inverness”), Miraculins and Mount Sinai Hospital (“MSH”) have agreed to certain amendments to the royalty and fee structure (the “Amendments”) of their License Agreement originally announced on October 15, 2008.
Read More
|
|
WINNIPEG, Manitoba – June 25th, 2009– Miraculins Inc. (TSX-V:MOM), a Canadian company focused on developing and commercializing medical diagnostic tests for unmet clinical needs, is pleased to announce the finalization of a Research Collaboration Agreement with Diagnostic Technologies Ltd. (DTL), an Israel based developer of diagnostic kits and devices for monitoring pregnancy disorders. In addition, Miraculins also announces the execution of a Cooperation and Project Funding Agreement with DTL and CIIRDF (Canada-Israel Industrial Research and Development Foundation).
Read More
|
|
WINNIPEG, Manitoba – August 28, 2009 – Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, today announces that it has agreed to issue 94,412 of its common shares to Diagnos Inc. at a price of $0.05 per common share (net cash value of $4,720.60) as part of the compensation owing for services rendered in accordance with the terms of an agreement between the parties announced December 4, 2007.
Read More
|
|
WINNIPEG, Manitoba – April 27, 2009 - Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, today announces a non-brokered private placement offering (the “Offering”) of up to 5,000,000 units (“Units”) at a price of $0.05 per Unit for gross proceeds of up to $250,000. Each Unit will be comprised of one common share of the Company (a “Share”) and one Share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to purchase one Share at a price of $0.10 per Share for a period of 24 months from the date the Warrant is issued.
Read More
|
|
|